Silexion Therapeutics (SLXN, Financial) has announced that it will execute a 1-for-15 reverse stock split of its common shares. This adjustment is scheduled to take effect following the market close on July 28, 2025. Subsequently, the company's shares will trade on a split-adjusted basis under the ticker symbol "SLXN" on the Nasdaq Capital Market starting from the market open on July 29, 2025.
The reverse split will merge every fifteen existing shares into a single share, with a new CUSIP number being assigned to these consolidated shares. The par value of each share will rise in proportion from $0.0009 to $0.0135. No fractional shares will be distributed; instead, any shareholders entitled to fractional shares through the DTC system will receive a full share through rounding up.
